Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00122512
Status:
TERMINATED
Last Update Posted:
2006-02-10
First Post:
2005-07-19
Brief Title:
Study of Tenofovir Disoproxil Fumarate TDF for Prevention of HIV
Sponsor:
FHI 360
Organization:
FHI 360
Conditions & Keywords Data
Conditions:
| Name |
|---|
| HIV Infections |
Keywords:
| Name | View |
|---|---|
| HIV Seronegativity | View |
| AE adverse event | View |
| AIDS acquired immunodeficiency syndrome | View |
| ALT SGPT alanine aminotransferase | View |
| ART antiretroviral therapy | View |
| AST SGOT aspartate aminotransferase | View |
| DCF data collection forms | View |
| DMC Data Monitoring Committee | View |
| FDA US Food and Drug Administration | View |
| GCP Good Clinical Practice guidelines | View |
| HB sAg Hepatitis B surface antigen | View |
| ICH International Conference of Harmonisation | View |
| IND Investigational New Drug Application | View |
| IRB Institutional Review Board | View |
| IU international units | View |
| mg milligrams | View |
| mm3 cubic millimeters | View |
| PCR polymerase chain reaction | View |
| SAE serious adverse event | View |
| TDF tenofovir disoproxil fumarate GS-4331-05 PMPA prodrug | View |
| µg microgram | View |
| ULN upper limit of the normal range | View |
| WB Western Blot | View |
| Human Immunodeficiency Virus | View |